Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Chloral hydrate may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for Welldorm Elixir contains chloral hydrate, which is one of a group of medicines called hypnotics (sleep inducing drugs). Adults: Welldorm Elixir is used for the short-term (maximum 2 weeks) treatment of severe sleeplessness (insomnia) which is interfering with normal daily life and where non-drug therapies (such as behavioural therapy and sleep hygiene) and other drugs have failed. Welldorm Elixir should be used in addition to non-drug therapies. Children and adolescents aged 2 years and above: Welldorm Elixir is used for the short-term (maximum 2 weeks) treatment of severe sleeplessness (insomnia) in children and adolescents with suspected or definite disorders that affect the development of the neurological system and brain (neurodevelopmental disorder). It is only used when the sleeplessness interferes with normal daily life and other therapies (non-drug therapies and other drugs) have failed. Welldorm Elixir should be used in addition to behavioural therapy and sleep hygiene management. The use of Welldorm Elixir in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist.
e Welldorm Elixir Do not take Welldorm Elixir if you:
1 uk-pil-Welldorm Elixir
Warnings and precautions Talk to your doctor, pharmacist or nurse before taking Welldorm Elixir:
Laboratory Tests If you are having blood tests for your thyroid, tell your doctor or nurse that you are taking this medicine, as chloral hydrate may interfere with these tests.
Welldorm Elixir Always take Welldorm Elixir exactly as your doctor has told you. You should check with your doctor or pharmacist if you are not sure. For Welldorm Elixir to work successfully, your doctor will need to identify the most appropriate dose for treating your sleeplessness. A higher strength Chloral Hydrate Oral Solution is available (500mg/5ml). Your doctor will help you to select the most appropriate strength and dose. Welldorm Elixir should be administered as a single daily dose, 15-30 minutes before bedtime, with water or milk. The usual recommended doses for Welldorm Elixir are: Adults and Children aged 12 years and over and the Elderly: The usual starting dose in 430-860 mg (15-30 ml of the 143mg/5ml strength). In the frail elderly or patients with liver problems a smaller dose may be required. Not more than 70 ml of the 143mg/5ml strength Welldorm Elixir (equivalent to 2 g of Chloral Hydrate) should be taken in any one day. Children 2 – 11 years: The use of Welldorm Elixir in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist. The dose will be calculated by your doctor or pharmacist based on the weight of the child. You should follow their instructions. Not more than 35 ml of the 143mg/5ml strength Welldorm Elixir (equivalent to 1 g of Chloral Hydrate) should be taken in any one day. If you are unsure about how to take your medicine, ask your doctor or pharmacist. Duration of treatment and stopping treatment Welldorm Elixir is usually prescribed for the short term treatment of sleeping problems when other non-medication treatments (e.g. behavioural therapy and sleep hygiene) have failed, for a maximum treatment period of 2 weeks. Repeat courses of Welldorm Elixir are not recommended and can only be administered following medical specialist re-assessment, because there is a risk of abuse and dependence. If you take Welldorm Elixir over a long period of time, you may find that the medicine takes longer to work and the effect does not last for as long. This is called "tolerance" to the chloral hydrate ingredient. If you find you are becoming "tolerant" to Welldorm Elixir do not increase the amount you take. Speak to your doctor. Following prolonged treatment with Welldorm Elixir the dose should be slowly reduced before discontinuation, because there is a risk of withdrawal symptoms. Suddenly stopping Welldorm Elixir may cause delirium (severe confusion). Contact your doctor before you stop taking the medicine, as they will advise you how to stop. If you take more Welldorm Elixir than you should In the event of an accidental overdose, contact your nearest hospital casualty department or tell your doctor immediately. It is advisable to have the medicine in its original packaging available for the doctor or hospital. Signs of an overdose include, vomiting, breathing problems, abnormal heartbeat, abnormally low body temperature, pinpoint pupils, low blood pressure or coma. If you forget to take Welldorm Elixir 3 uk-pil-Welldorm Elixir
If you have missed one dose, this dose should be omitted, and the next dose should be taken at the usual time. Do not take a double dose to make up for a forgotten dose.
Like all medicines, this medicine can cause side effects, although not everybody gets them. Stop taking the medicine and seek urgent medical advice if you have: • • • • •
Hypersensitivity and allergic reactions such as itchy skin, skin redness and swelling and skin rash, sudden wheezing, swelling of the face, lips, tongue, throat, or body, rash, fainting or difficulty breathing or swallowing. Difficulty in breathing (dyspnoea) or very slow and/or shallow breathing (respiratory depression), Heart problems such as slow, fast or irregular heartbeat (which might reflect serious heart problems such as QTc prolongation) Sudden or severe confusion (delirium) Kidney injury with symptoms such as reduced urine output
Tell your doctor if you notice any of the following side effects or notice any other effects not listed: • • • • • • • • •
Headache Mental side effects such as anxiety, restlessness, excitation or confusion Loss of coordination of muscle movements (ataxia) Stomach and intestinal problems such as abdominal pain, distension of the abdomen, flatulence, nausea and vomiting (as these might reflect serious problems such as stomach irritation, gastric necrosis, gastric perforation or gut swelling) Long-term use of this medication leading to tolerance (usual doses not producing the desired effect) Dependence on the medication and its abuse Chronic intoxication with mental symptoms or any other symptoms described here Withdrawal symptoms which may be severe and include hallucinations and delirium Ketonuria (a condition in which ketone bodies are present in the urine) detected by tests as advised by your doctor
If you are elderly you may be more susceptible to confusion and co-ordination problems which may lead to falls and injury. In new-borns and children <2 years of age, there is an increased risk of side effects. Do not give to a child under 2 years of age. If any of the symptoms become troublesome, or if you notice anything else not mentioned here, please go and see your doctor. He/she may want to adjust the dose or give you a different medicine. Reporting of side effects If you get any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the Yellow card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting the side effects you can help provide more information on the safety of this medicine.
Welldorm Elixir Store below 25oC. Keep the bottle upright in the outer carton to protect from light. Use within 28 days of opening Keep this medicine out of the sight and reach of children. 4 uk-pil-Welldorm Elixir
Do not use Welldorm Elixir after the expiry date which is stated on the bottle label and carton after "EXP". The expiry date refers to the last day of the month. Do not throw away any medicines via waste water or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.
What Welldorm Elixir contain The active substance in Chloral Hydrate Oral Solution is chloral hydrate. Chloral Hydrate Oral Solution also contains glycerol (E 422), liquid glucose, sodium benzoate (E 211), sodium citrate (E 331), citric acid monohydrate (E 330), saccharin sodium (E 954), essence of passion fruit (containing natural flavouring, artificial flavouring, propylene glycol (E1520)), and purified water. What Welldorm Elixir look likes and contents of the pack Welldorm elixir is a clear, solution with a fruity odour containing 143.3 mg chloral hydrate per 5 ml. A pack size of 150 ml is available. Marketing Authorisation Holder Marlborough Pharmaceuticals Ltd, Sovereign House, Miles Gray Road, Basildon, Essex, SS14 3FR, United Kingdom Manufacturer LABORATORIUM SANITATIS, S.L. Leonardo da Vinci, 11 Parque Tecnológico de Álava, Miñano, 01510 Alava Spain Waymade PLC Sovereign House, Miles Gray Road, Basildon, Essex SS14 3FR. United Kingdom The Product Licence number is PL 23138/0016.
For information in large print tape, CD or Braille, telephone 01279 406759 This leaflet was last revised in April 2022.
5 uk-pil-Welldorm Elixir
The active substance in Welldorm Elixir is chloral hydrate.
This leaflet reproduces the patient information leaflet approved for Welldorm Elixir, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Adults:
Chloral Hydrate Oral Solution is indicated for the short-term treatment (maximum 2 weeks) of severe insomnia which is interfering with normal daily life and where other therapies (behavioural and pharmacologic) have failed.
Chloral Hydrate Oral Solution should be used as an adjunct to non- pharmacological therapies.
Children and adolescents aged 2 years and above:
Chloral hydrate Oral Solution is indicated for short-term treatment (maximum 2 weeks) of severe insomnia in children and adolescents with suspected or definite neurodevelopmental disorder, when the insomnia is interfering with normal daily life and other therapies (behavioural and pharmacologic) have failed.Treatment should be as an adjunct to behavioural therapy and sleep hygiene management.
The use of Chloral Hydrate Oral Solution in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist.
Conditions for use
The treatment should be as short as possible and should not exceed the maximum treatment period of 2 weeks.
Repeat courses of chloral hydrate are not recommended and can only be administered following medical specialist re-assessment, since the risk of abuse and dependence increases with the duration of treatment (see section 4.4).
Following prolonged treatment with chloral hydrate the dose should be slowly tapered before discontinuation.
The use of Chloral Hydrate Oral Solution in children and adolescents is not generally recommended and if used should be under the supervision of a medical specialist (see section 4.1).
Posology
Chloral Hydrate 143mg/5ml Oral Solution should be administered as a single daily dose, between 15 to 30 minutes before bedtime with water or milk.
Adults:
The usual dose is 430-860 mg (15-30 ml of the 143mg/5ml strength). Higher doses should not exceed a maximum of 2 g chloral hydrate (70 ml of the 143mg/5ml strength) per dose.
Elderly:
Dosage as for adults, except for the frail elderly or those with hepatic impairment where a reduction in dose may be appropriate (see section 4.4).
Paediatric population
Children 12 years and over:
The usual dose is 430-860 mg (15-30 ml of the 143mg/5ml strength). Higher doses should not exceed a maximum of 2 g chloral hydrate (70 ml of the 143mg/5ml strength) per dose.
Children (between 2 and 11 years):
30-50 mg/kg (1-1.75 ml/kg of the 143mg/5ml strength) of bodyweight. The dose should not exceed 1 g chloral hydrate (35 ml of the 143 mg/5ml strength) per dose.
Children under 2 years:
Chloral hydrate should not be used because the safety and efficacy of chloral hydrate in children aged under 2 years has not been established (see sections 4.4).
Hepatic impairment:
Chloral hydrate is contraindicated in patients with severe hepatic impairment (see section 4.3). Specific guidelines for dosage adjustments in mild and moderate hepatic impairment are not available; chloral hydrate is extensively metabolized by the liver and, therefore, dose adjustments may be warranted.
Renal impairment:
Chloral hydrate is contraindicated in patients with renal failure or severe renal impairment (see section 4.3). Specific guidelines for dosage adjustments in mild and moderate renal impairment are not available; dose adjustments may be warranted.
Method of administration
Oral.
Chloral Hydrate 143mg/5ml Oral Solution does not require dilution.
- Hypersensitivity to chloral hydrate or to any of the excipients listed in section 6.1.
- in patients with severe hepatic impairment,
- in patients with severe renal impairment,
- in patients with severe cardiac disease,
- in patients with active gastritis, oesophagitis, gastric or duodenal ulcers or perforation,
- in patients susceptible to acute attacks of porphyria.
Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.2).
Tolerance, dependence, withdrawal, misuse
Tolerance, dependence and withdrawal symptoms have been reported with chloral hydrate. Abrupt discontinuation should not be undertaken in patients receiving prolonged treatment with chloral hydrate. Sudden withdrawal of the drug may cause delirium and hallucinations. Slowly withdraw chloral hydrate.
Individuals with a history of alcohol or drug abuse or dependence may be at greater risk for abuse and misuse of chloral hydrate. Prior to prescribing chloral hydrate, each patient's risk for abuse or misuse should be assessed and patients receiving chloral hydrate should be monitored for the development of behaviours or conditions of abuse or misuse while on therapy.
Gastrointestinal disorders
Chloral hydrate should be used with caution in patients with history of gastritis, oesophagitis, gastric or duodenal ulceration or perforation. Chloral hydrate is contraindicated in patients with active gastritis, oesophagitis, gastric or duodenal ulcers or perforation (see section 4.3).
Hepatic and renal impairment
Chloral hydrate should be used with caution in patients with mild to moderate hepatic and renal impairment and is contraindicated in patients with severe hepatic and renal impairment (see sections 4.2 and 4.3).
Elderly patients
Elderly patients are more likely to experience the undesirable effects of hypnotics such as ataxia and confusion which may lead to falls and injury. For use in the frail elderly, it is recommended that the lowest effective dose be administered (see section 4.2 and 4.5).
QT prolongation
Chloral hydrate should be used with caution and particular care in patients with low potassium levels, bradyarrhythmia, congenital long QT syndrome and other heart disorders (especially arrhythmia) (see sections 4.5 and 4.8).
Paediatric population
Due to immaturity of hepatic metabolism in neonates and children <2 years of age, there is a risk of extended half-life of chloral hydrate and increased risk of undesirable effects (see section 5.2).
Excipient warnings in the formulation
Liquid Glucose: Patients with rare glucose-galactose malabsorption should not take this medicine.
Sodium benzoate: This medicine contains 6.3 mg of sodium benzoate in each 5 ml, which is equivalent to 1.26 mg/ml. Sodium benzoate may increase bilirubinaemia in neonates, resulting in neonatal jaundice which may develop into kernicterus.
Propylene glycol: This medicine contains 18.39 mg propylene glycol in each 5 ml which is equivalent to 3.678 mg/ ml. Co-administration with any substrate for alcohol dehydrogenase such as ethanol may induce serious adverse effects in neonates.
Glycerol: May cause headache, stomach upset and diarrhoea.
This medicine contains less than 1 mmol sodium (23 mg) per 5 ml, which is to say it is essentially 'sodium-free'.
No formal assessments of pharmacokinetic interactions between chloral hydrate and other therapeutic medicinal products have been conducted.
Concomitant use of alcohol and chloral hydrate may potentiate the sedative effect; concomitant use should be avoided.
In combination with CNS depressants an enhancement of the central depressive effect may occur. Concomitant use with antipsychotics, hypnotics, anxiolytics/sedatives, antidepressant agents, centrally acting muscle relaxants, narcotic analgesics, anti-epileptic drugs, anaesthetics and sedative antihistamines should be avoided.
The concomitant use of drugs that also prolong the QT interval in ECG (for example, antiarrhythmics of Class IA or III, antibiotics, agents against malaria, H1 antihistamines, antipsychotics or medicinal products known to cause hypokalaemia or hypomagnesaemia) can lead to cardiac arrhythmias (see sections 4.4 and 4.8).
Chloral hydrate followed by intravenous furosemide may result in sweating, hot flushes and variable blood pressure including hypertension due to a hypermetabolic state caused by displacement of thyroid hormone from its bound state.
Delirium may occur, especially in the elderly, particularly when used in conjunction with psychotropics or anticholinergics.
In patients taking anticoagulants, when chloral hydrate is added to or withdrawn from the drug regimen, or its dosage changed, careful monitoring of the prothrombin time is required.
Chloral Hydrate may interfere with laboratory tests of thyroid function.
Chloral Hydrate oral Solution should not be used in pregnancy and lactation.
Pregnancy
Little information is available on the possible adverse effects of chloral hydrate on human pregnancy. Chloral hydrate is known to cross the human placenta at term, but its use during relatively few pregnancies did not cause a detectable increase in abnormal outcomes. Some data suggest that prolonged administration of sedative doses of chloral hydrate to neonates increases the likelihood of hyperbilirubinemia.
Breast Feeding
Low levels of chloral hydrate have been found in breast milk. Although breastfeeding infants may be sedated by chloral hydrate in breast milk, the highest concentration measured in the milk (about 15 µg/ml) was considerably lower than that which would be measured in blood at a clinically active dose (100 µg/ml).
Fertility
There is no information relating to the effects of Chloral Hydrate Oral Solution on fertility.
Patients receiving Chloral Hydrate Oral Solution should be warned that their ability to drive or use machinery may be impaired by drowsiness.
The following adverse reactions have been reported. The frequency grouping is defined using the following convention: Very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to
<1/1,000); very rare (<1/10,000); not known (cannot be estimated from the available data).
Immune system disorders:
Not known: hypersensitivity, allergic skin reactions
Metabolism and nutrition disorders:
Not known: ketonuria
Psychiatric disorders:
Not known: anxiety, hyperactivity, confusion, tolerance, dependence, delirium, abuse, chronic intoxication, withdrawal symptoms
Nervous system disorders:
Not known: headache, ataxia
Respiratory, thoracic and mediastinal disorders:
Not known: dyspnoea, respiratory depression
Cardiac disorders:
Not known: QTc prolongation, arrhythmias (see sections 4.4 and 4.5)
Gastrointestinal disorders:
Not known: gastric irritation, abdominal distension, flatulence, gastric necrosis, gastric perforation, nausea, vomiting, gastritis
Renal and urinary disorders:
Not known: parenchymatous renal injury
Elderly patients
Ataxia, confusion, falls and injuries.
Paediatric population
In neonates and children <2 years of age, there is an increased risk of undesirable effects (see section 4.4).
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.
The signs and symptoms of overdose involve the cardiovascular, respiratory and central nervous systems. These may include: respiratory depression, arrhythmias, hypothermia, pin-point pupils, hypotension or coma. Gastric irritation may result in vomiting and even gastric necrosis. If the patient survives, icterus due to hepatic damage and albuminuria from renal damage may appear. Serious problems have arisen with doses as little as 4g and 10g can be fatal. Overdosage should be treated with gastric lavage or inducing vomiting to empty the stomach. Supportive measures must be used.
Haemodialysis, and in some cases haemoperfusion, have been reported to be effective in promoting the clearance of trichloroethanol.
Ask anything about Welldorm Elixir. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.